Sucampo, Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation

Sucampo Pharmaceuticals

and its development and commercialization partner Takeda Pharmaceuticals U.S.A., Inc.

today announced that Sucampo Pharma Americas, LLC (SPA) initiated a pivotal clinical trial of a liquid form of lubiprostone 24 mcg BID in adult subjects with chronic idiopathic constipation (CIC).